Revenue Recognition and Accounts Receivable

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue Recognition and Accounts Receivable

Revenue Recognition and Accounts Receivable

The following table presents the Company’s net sales by product category for each of our reportable segments for the years ended December 31, 2021, 2020, and 2019, respectively:

(In millions)	2021 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	5,759.2		2,207.8		1,197.1		1,677.2		10,841.3
Complex Gx and Biosimilars	1,241.6		0.2		46.5		53.8		1,342.1
Generics	3,427.9		4.8		783.8		1,413.7		5,630.2
Total Viatris	$	10,428.7	$	2,212.8	$	2,027.4	$	3,144.7	$	17,813.6

(In millions)	2020 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	3,920.7		253.9		617.0		443.3		5,234.9
Complex Gx and Biosimilars	1,202.6		0.7		42.8		49.4		1,295.5
Generics	3,387.6		5.3		535.5		1,361.1		5,289.5
Total Viatris	$	8,510.9	$	259.9	$	1,195.3	$	1,853.8	$	11,819.9

(In millions)	2019 Net Sales
Product Category	Developed Markets		Greater China		JANZ		Emerging Markets		Total
Brands	4,199.1		207.6		533.3		422.1		5,362.1
Complex Gx and Biosimilars	1,127.4		0.4		23.8		59.7		1,211.3
Generics	2,913.5		6.6		635.4		1,241.4		4,796.9
Total Viatris	$	8,240.0	$	214.6	$	1,192.5	$	1,723.2	$	11,370.3

The following table presents net sales on a consolidated basis for select key products for the year ended December 31, 2021:

(In millions)	Year Ended December 31, 2021
Select Key Global Products
Lipitor ®	$	1,663.2
Norvasc ®	824.7
Lyrica ®	728.5
Viagra ®	533.8
EpiPen® Auto-Injectors	391.7
Celebrex ®	344.4
Effexor ®	316.8
Creon ®	309.8
Zoloft ®	284.3
Xalabrands	226.0
Select Key Segment Products
Influvac ®	$	299.3
Amitiza ®	201.5
Xanax ®	185.9
Dymista ®	168.0
Yupelri ®	161.9

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Prior periods are not presented due to significance of products acquired as part of the Combination.

Variable Consideration and Accounts Receivable    

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the years ended December 31, 2021, 2020 and 2019, respectively:

	Year Ended December 31,
(In millions)	2021		2020		2019
Gross sales	$	30,553.4	$	19,899.1	$	19,012.2
Gross to net adjustments:
Chargebacks	(5,530.1)		(3,656.2)		(3,309.6)
Rebates, promotional programs and other sales allowances	(6,135.6)		(3,765.5)		(3,629.3)
Returns	(384.6)		(329.7)		(237.9)
Governmental rebate programs	(689.5)		(327.8)		(465.1)
Total gross to net adjustments	$	(12,739.8)	$	(8,079.2)	$	(7,641.9)
Net sales	$	17,813.6	$	11,819.9	$	11,370.3

The following is a rollforward of the categories of variable consideration during 2021:

(In millions)	Balance at December 31, 2020		Current Provision Related to Sales Made in the Current Period		Measurement Period Adjustments and Reclasses		Checks/ Credits Issued to Third Parties		Effects of Foreign Exchange		Balance at December 31, 2021
Chargebacks	$	585.2	$	5,530.1	$	63.4	$	(5,585.4)	$	(1.6)	$	591.7
Rebates, promotional programs and other sales allowances	1,576.3		6,135.6		(57.6)		(6,267.1)		(14.2)		1,373.0
Returns	539.9		384.6		269.0		(499.0)		(7.7)		686.8
Governmental rebate programs	313.3		689.5		110.6		(705.2)		(9.0)		399.2
Total	$	3,014.7	$	12,739.8	$	385.4	$	(13,056.7)	$	(32.5)	$	3,050.7

Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net revenues and as a contra-asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). Accounts receivable are presented net of allowances relating to these provisions, which were comprised of the following at December 31, 2021 and 2020, respectively:

(In millions)	December 31, 2021		December 31, 2020
Accounts receivable, net	$	1,688.6	$	1,802.9
Other current liabilities	1,362.1		1,211.8
Total	$	3,050.7	$	3,014.7

We have not made and do not anticipate making any significant changes to the methodologies that we use to measure provisions for variable consideration; however, the balances within these reserves can fluctuate significantly through the consistent application of our methodologies. Historically, we have not recorded in any current period any material amounts related to adjustments made to prior period reserves.